Atlas Trials

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

Clinical trial NCT05870839 · COMPLETED

Trial details

NCT number
NCT05870839
Sponsor
Vaccine Company, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
SARS-CoVSARS-CoV-2
Start date
2023-05-11
Primary completion
2024-04-10
Enrollment
121

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.